PMC:7377212 / 24011-24297
Annnotations
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T195 | 35-38 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T196 | 127-130 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T197 | 205-208 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T144 | 0-26 | Sentence | denotes | Conflict of interest: P.E. |
| T145 | 27-286 | Sentence | denotes | Verweij has received research grants from Gilead Sciences, F2G Ltd, Pfizer, Thermofisher and Merck, has served on an advisory board for Gilead Sciences, Mundipharma and F2G, and has received speaker honoraria from F2G, Mundipharma, Pfizer and Gilead Sciences. |